Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

BACKGROUND: More than 50% of metastatic melanoma patients have a specific mutation in the serine/threonine kinase BRAF. This results in constitutive activation of the RAS-RAF-MEK-ERK-MAP kinase pathway, which causes uncontrolled cell growth. Vemurafenib (PLX4032) is an oral chemotherapeutic agent th...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Jingjing, Egger, Michael E., McMasters, Kelly M., Hao, Hongying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014033/
https://www.ncbi.nlm.nih.gov/pubmed/29929490
http://dx.doi.org/10.1186/s12885-018-4583-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014033/
https://www.ncbi.nlm.nih.gov/pubmed/29929490
http://dx.doi.org/10.1186/s12885-018-4583-3

Ejemplares similares